The Food and Drug Administration granted Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) fast track status for its cancer drug Perifosine sending the stock price up 37 cents to close at $3.02.
FDA Fast Tracks Keryx's Perifosine
December 02, 2009 at 17:52 PM EST